242 related articles for article (PubMed ID: 32734668)
1. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
Smith G; Apperley J; Milojkovic D; Cross NCP; Foroni L; Byrne J; Goringe A; Rao A; Khorashad J; de Lavallade H; Mead AJ; Osborne W; Plummer C; Jones G; Copland M;
Br J Haematol; 2020 Oct; 191(2):171-193. PubMed ID: 32734668
[No Abstract] [Full Text] [Related]
2. [Chronic myeloid leukemia].
Usui N
Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
[TBL] [Abstract][Full Text] [Related]
3. [Management of advanced stage chronic myeloid leukemia].
Takahashi N
Rinsho Ketsueki; 2014 Oct; 55(10):1860-9. PubMed ID: 25297750
[No Abstract] [Full Text] [Related]
4. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
5. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
6. The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML).
Wolfe HR; Rein LAM
Curr Hematol Malig Rep; 2021 Oct; 16(5):448-454. PubMed ID: 34661874
[TBL] [Abstract][Full Text] [Related]
7. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
8. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
Kimura S
Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
[No Abstract] [Full Text] [Related]
9. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
Samis J; Lee P; Zimmerman D; Arceci RJ; Suttorp M; Hijiya N
Pediatr Blood Cancer; 2016 Aug; 63(8):1332-8. PubMed ID: 27100618
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials in chronic myeloid leukemia.
Saussele S; Pfirrmann M
Curr Hematol Malig Rep; 2012 Jun; 7(2):109-15. PubMed ID: 22422549
[TBL] [Abstract][Full Text] [Related]
11. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.
Marin D
Hematology Am Soc Hematol Educ Program; 2012; 2012():115-21. PubMed ID: 23233569
[TBL] [Abstract][Full Text] [Related]
12. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
14. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
15. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib more effective than imatinib in CML.
Gourd E
Lancet Oncol; 2017 Dec; 18(12):e716. PubMed ID: 29129440
[No Abstract] [Full Text] [Related]
17. Management of patients with resistant or refractory chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Oncology (Williston Park); 2008 Apr; 22(4):430-7; discussion 437, 442, 446 passim. PubMed ID: 18472616
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: Valuable therapeutic option for the Bulgarian market.
Uzunova KH; Filipova EP; Vekov TY
J Cancer Res Ther; 2018; 14(5):909-915. PubMed ID: 30197324
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia. Introduction.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S2-3. PubMed ID: 18056928
[No Abstract] [Full Text] [Related]
20. [Chronic Myelogenous Leukemia].
Hochhaus A; Eigendorff E; Ernst T
Dtsch Med Wochenschr; 2018 Sep; 143(18):1304-1310. PubMed ID: 30199910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
